
    
      Vopratelimab is an agonist monoclonal antibody that specifically binds to the Inducible
      CO-Stimulator of T cells (ICOS) to generate an anti-tumor immune response. This is an open
      label, roll over study to evaluate the long-term safety of continued treatment with
      vopratelimab monotherapy or combination treatment.
    
  